valproic acid has been researched along with Bladder Cancer in 9 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "High grade invasive bladder cancer is a leading cause of cancer deaths and treatment options are limited for this type of cancer." | 5.35 | Differential effects of valproic acid on growth, proliferation and metastasis in HTB5 and HTB9 bladder cancer cell lines. ( Byun, SS; Khandrika, L; Kim, FJ; Koul, HK; Koul, S; Kumar, B; Wilson, S, 2009) |
| "The influence of the histone deacetylase (HDAC)-inhibitor, valproic acid (VPA), on bladder cancer cell adhesion in vitro was investigated in this paper." | 3.79 | HDAC inhibition suppresses bladder cancer cell adhesion to collagen under flow conditions. ( Bartsch, G; Blaheta, RA; Haferkamp, A; Hudak, L; Juengel, E; Makarevic, J; Meyer dos Santos, S; Schneider, T; Wiesner, C, 2013) |
| "Our aim was to analyze the impact of the histone deacetylase (HDAC)-inhibitor valproic acid (VPA) on bladder cancer cell growth in vitro." | 3.77 | HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro. ( Blaheta, RA; Haferkamp, A; Hudak, L; Juengel, E; Tsaur, I; Vallo, S; Wiesner, C; Xi, W, 2011) |
| "Treatment of HTB5 and HTB9 bladder cancer cells for 24 to 72 hours with valproic acid and mitomycin C resulted in concentration and time dependent decreases in viability and proliferation." | 3.77 | Potentiation of mitomycin C tumoricidal activity for transitional cell carcinoma by histone deacetylase inhibitors in vitro. ( Deb, AA; Koul, HK; Koul, S; Kumar, B; Lim, DD; Meacham, RB; Rove, KO; Wilson, SS, 2011) |
| "To examine the expression profile of histone deacetylase (HDAC)-1 and explore its potential role in the development of bladder cancer, using valproic acid (VPA), a HDAC inhibitor, which reduces tumour growth and metastasis formation in animal models." | 3.76 | Inhibition of bladder tumour growth by histone deacetylase inhibitor. ( Kikugawa, T; Miura, N; Ozawa, A; Sasaki, T; Tanji, N; Yanagihara, Y; Yokoyama, M, 2010) |
| "The aim of this study wsa to evaluate the additive effect of valproic acid (VPA) to γδ T-cell cytotoxicity against bladder cancer cells." | 3.76 | The antitumour effect of {gamma}{delta} T-cells is enhanced by valproic acid-induced up-regulation of NKG2D ligands. ( Acharya, B; Gotoh, A; Naoe, M; Okamura, H; Suzuki, T; Terao, S; Yamamoto, S, 2010) |
| "Prevention of bladder cancer recurrence is a central challenge in the management of this highly prevalent disease." | 1.38 | Valproic acid decreases urothelial cancer cell proliferation and induces thrombospondin-1 expression. ( Bratslavsky, G; Byler, TK; Leocadio, D; Messing, EM; Reeder, JE; Shapiro, O; Stodgell, CJ; Wood, RW, 2012) |
| "Bladder cancer is one of the most common malignancies and causes hundreds of thousands of deaths worldwide each year." | 1.37 | Histone deacetylases (HDACs) in XPC gene silencing and bladder cancer. ( Abrams, J; Wang, G; Wang, L; Xu, XS, 2011) |
| "High grade invasive bladder cancer is a leading cause of cancer deaths and treatment options are limited for this type of cancer." | 1.35 | Differential effects of valproic acid on growth, proliferation and metastasis in HTB5 and HTB9 bladder cancer cell lines. ( Byun, SS; Khandrika, L; Kim, FJ; Koul, HK; Koul, S; Kumar, B; Wilson, S, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Juengel, E | 2 |
| Meyer dos Santos, S | 1 |
| Schneider, T | 1 |
| Makarevic, J | 1 |
| Hudak, L | 2 |
| Bartsch, G | 1 |
| Haferkamp, A | 2 |
| Wiesner, C | 2 |
| Blaheta, RA | 2 |
| Byun, SS | 1 |
| Kim, FJ | 1 |
| Khandrika, L | 1 |
| Kumar, B | 2 |
| Koul, S | 2 |
| Wilson, S | 1 |
| Koul, HK | 2 |
| Ozawa, A | 1 |
| Tanji, N | 1 |
| Kikugawa, T | 1 |
| Sasaki, T | 1 |
| Yanagihara, Y | 1 |
| Miura, N | 1 |
| Yokoyama, M | 1 |
| Suzuki, T | 1 |
| Terao, S | 1 |
| Acharya, B | 1 |
| Naoe, M | 1 |
| Yamamoto, S | 1 |
| Okamura, H | 1 |
| Gotoh, A | 1 |
| Xu, XS | 1 |
| Wang, L | 1 |
| Abrams, J | 1 |
| Wang, G | 1 |
| Vallo, S | 1 |
| Xi, W | 1 |
| Tsaur, I | 1 |
| Deb, AA | 1 |
| Wilson, SS | 1 |
| Rove, KO | 1 |
| Lim, DD | 1 |
| Meacham, RB | 1 |
| Byler, TK | 1 |
| Leocadio, D | 1 |
| Shapiro, O | 1 |
| Bratslavsky, G | 1 |
| Stodgell, CJ | 1 |
| Wood, RW | 1 |
| Messing, EM | 1 |
| Reeder, JE | 1 |
| Chen, CL | 1 |
| Sung, J | 1 |
| Cohen, M | 1 |
| Chowdhury, WH | 1 |
| Sachs, MD | 1 |
| Li, Y | 1 |
| Lakshmanan, Y | 1 |
| Yung, BY | 1 |
| Lupold, SE | 1 |
| Rodriguez, R | 1 |
9 other studies available for valproic acid and Bladder Cancer
| Article | Year |
|---|---|
HDAC inhibition suppresses bladder cancer cell adhesion to collagen under flow conditions.
Topics: Carcinoma; Cell Adhesion; Cell Line, Tumor; Collagen; Flow Cytometry; Histone Deacetylase Inhibitors | 2013 |
Differential effects of valproic acid on growth, proliferation and metastasis in HTB5 and HTB9 bladder cancer cell lines.
Topics: Antineoplastic Agents; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Prolifer | 2009 |
Inhibition of bladder tumour growth by histone deacetylase inhibitor.
Topics: Animals; Cell Proliferation; Enzyme Inhibitors; Female; Histone Deacetylase 1; Humans; Immunohistoch | 2010 |
The antitumour effect of {gamma}{delta} T-cells is enhanced by valproic acid-induced up-regulation of NKG2D ligands.
Topics: Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cytotoxicity, Immunologic; GABA Agents; Gen | 2010 |
Histone deacetylases (HDACs) in XPC gene silencing and bladder cancer.
Topics: Caspase 3; Cell Line, Tumor; Cell Transformation, Neoplastic; Chromatin Immunoprecipitation; Cisplat | 2011 |
HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro.
Topics: CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 2; Cy | 2011 |
Potentiation of mitomycin C tumoricidal activity for transitional cell carcinoma by histone deacetylase inhibitors in vitro.
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Drug Synergism; Drug Therapy, Combination | 2011 |
Valproic acid decreases urothelial cancer cell proliferation and induces thrombospondin-1 expression.
Topics: Cell Line, Tumor; Cell Proliferation; Down-Regulation; Gene Expression Regulation, Neoplastic; Human | 2012 |
Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells.
Topics: Acetylation; Animals; Cell Line, Tumor; Cell Movement; Cell Survival; Coxsackie and Adenovirus Recep | 2006 |